Summary
EudraCT Number: 2005-003485-42
Sponsor's Protocol Code Number: BY1023/M3-341
National Competent Authority: Belgium - FPS Health-DGM 
Clinical Trial Type: EEA CTA
Trial Status: Completed
Date on which this record was first entered in the EudraCT database: 2006-07-06
Link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003485-42/BE/

A. Protocol Information
A.1 Member State Concerned: Belgium - FPS Health-DGM
A.2 EudraCT number: 2005-003485-42
A.3 Full title of the trial: Treatment response in patients with symptoms due to gastroesophageal reflux disease either with or without esophagitis treated with pantoprazole sodium 40 mg o.d. over 8 weeks

A.3.2 Name or abbreviated title of the trial where available: REAL LIFE
A.4.1 Sponsor's protocol code number: BY1023/M3-341
A.7 Trial is part of a Paediatric Investigation Plan: Information not present in EudraCT
A.8 EMA Decision number of Paediatric Investigation Plan: 

B. Sponsor Information
Sponsor 1
B.1.1 Name of Sponsor: ALTANA Pharma AG
B.1.3.4	Country: Germany
B.3.1 and B.3.2	Status of the sponsor: Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1 Name of organisation providing support:
B.4.2 Country:
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1 Name of organisation: 
B.5.2 Functional name of contact point: 

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Information not present in EudraCT
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: Pantoprazole Sodium 
D.3.4 Pharmaceutical form: Tablet
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: Pantoprazole Sodium
D.3.9.1 CAS number: 102625-70-7
D.3.9.3 Other descriptive name: Pantoprazole-Sodium-Sesquihydrate
D.3.10 Strength
D.3.10.1 Concentration unit: mg milligram(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 40 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: Information not present in EudraCT
D.3.11.8 Extractive medicinal product: Information not present in EudraCT
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No

D.8 Information on Placebo

E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1 Medical condition(s) being investigated: gastroesophageal reflux disease
MedDRA Classification
E.1.2 Medical condition or disease under investigation:
E.1.2 Version: 8.1
E.1.2 Level: llt
E.1.2 Classification code: 10017885
E.1.3 Condition being studied is a rare disease: No
E.2 Objective of the trial
E.2.1 Main objective of the trial: The objective of the present study is the identification of factors (e.g. symptom patterns and symptom scores) determining the response to treatment with pantoprazole 40 mg o.d. as measured by different methods (e.g. ReQuest™ questionnaire, patient and investigator assessment).
E.2.2 Secondary objectives of the trial: 
E.2.3 Trial contains a sub-study: Information not present in EudraCT
E.3 Principal inclusion criteria: - Written informed consent by the patient for study participation, prior to protocol specific procedures
- Outpatients of at least 18 years of age (21 years in Argentina)
- Patient considered by the investigator to have symptoms due to gastroesophageal reflux disease
- Patients whose compliance is expected to be high with respect to the completion of the questionnaires and diaries (ReQuest™, GERDyzer™, HADS, TSS) according to the assessment of the investigator

E.4 Principal exclusion criteria: Signs, indicating other gastrointestinal diseases:
- Zollinger-Ellison syndrome or other gastric hypersecretory condition 
- Previous acid-lowering surgery or other surgery of the esophagus and/or upper gastrointestinal tract (exception: polypectomy and cholecystectomy) 
- On initial endoscopy, presence of obstructive esophageal strictures, Schatzki’s ring, esophageal diverticula, esophageal varices, achalasia or Barrett‘s esophagus with known high-grade dysplasia or longer than 3 cm
- Acute peptic ulcer and/or ulcer complications 
- Inflammatory bowel diseases

Other concomitant diseases:
- Severe or unstable cardiovascular (e.g., severe angina pectoris, postmyocardial infarction and ventricular extrasystoles), pulmonary, or endocrine disease; clinically significant renal or hepatic disease or dysfunction; hematologic disorder; any other clinically significant medical condition that could increase the risk to the study participant
- Malignant disease of any kind during the previous 5 years except for successfully treated skin (basal or squamous cell) cancer
- Tendency to react allergically to drugs, especially with known hypersensitivity to one of the compounds of the study medication 
- Alcohol, drug or medication abuse within the past year
- Clinically relevant abnormal laboratory values and vital signs suggesting an underlying disease and requiring further clinical evaluation 
- Severe psychiatric or neurologic disorders 

Special restrictions for female patients:
- Pregnant or nursing female patients
- Female patients of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, unless they are surgically sterilized / hysterectomized or who are not using any other method considered sufficiently reliable by the investigator in individual cases

Previous medication:
- PPIs during the last 10 days before the start of the study
- H2-receptor antagonists or prokinetics during the last 7 days before the start of the study 
- Any medication for the purpose of the eradication of H. pylori during the last 28 days before the start of the study
- Systemic glucocorticoids or non-steroidal anti-inflammatory drugs (NSAIDs) including COX-2-inhibitors (> 5 days on demand but not more than 3 consecutive days) during the last 28 days before the start of the study; except regular intake of acetylsalicylic acid in dosages up to 163 mg/d

Concomitant medication:
- PPIs (except study medication), H2-receptor antagonists, prokinetics, sucralfate, misoprostol, bismuth preparations or other substances, which may have an influence on the relief of acid-related symptoms 
- Systemic glucocorticoids or non-steroidal anti-inflammatory drugs (NSAIDs) including COX-2-inhibitors (> 5 days on demand but not more than  3 consecutive days) except regular intake of acetylsalicylic acid in dosages up to 163 mg/d  
- Ketoconazole or other drugs with pH-dependent absorption
- PPIs in combination with antibiotics for the purpose of the eradication of H. pylori
- Onset or change of psychotropic medication 

Others:
- Patients who are expected to be non-compliant and/or not co-operative
- Participation in a clinical study within the last 30 days prior to the start of the study
- Patients who have participated already in this study
- Patients who are employees at the investigational site, relatives or spouse of the investigator
- Any donation of germ cells, blood, organs, or bone marrow during the course of the study
- Patients who are not contractually capable

E.5 End points
E.5.1 Primary end point(s): The primary variable of this study is the response to treatment with pantoprazole 40 mg o.d. at week 8 as measured by ReQuest™-GI in relation to various response factors as measured by ReQuest™ and its subscales 	
E.6 and E.7 Scope of the trial
E.6 Scope of the Trial
E.6.1 Diagnosis: No
E.6.2 Prophylaxis: No
E.6.3 Therapy: No
E.6.4 Safety: No
E.6.5 Efficacy: Yes
E.6.6 Pharmacokinetic: No
E.6.7 Pharmacodynamic: No
E.6.8 Bioequivalence: No
E.6.9 Dose response: No
E.6.10 Pharmacogenetic: Information not present in EudraCT
E.6.11 Pharmacogenomic: No
E.6.12 Pharmacoeconomic: No
E.6.13 Others: No
E.7 Trial type and phase 
E.7.1 Human pharmacology (Phase I): No
E.7.1.1 First administration to humans: No
E.7.1.2 Bioequivalence study: No
E.7.1.3 Other: No
E.7.1.3.1 Other trial type description: 
E.7.2 Therapeutic exploratory (Phase II): No
E.7.3 Therapeutic confirmatory (Phase III): Yes
E.7.4 Therapeutic use (Phase IV): No
E.8 Design of the trial
E.8.1 Controlled: Yes
E.8.1.1 Randomised: No
E.8.1.2 Open: Yes
E.8.1.3 Single blind: No
E.8.1.4 Double blind: No
E.8.1.5 Parallel group: No
E.8.1.6 Cross over: No
E.8.1.7 Other: No
E.8.2 Comparator of controlled trial
E.8.2.1 Other medicinal product(s): No
E.8.2.2 Placebo: No
E.8.2.3 Other: No
E.8.3 The trial involves single site in the Member State concerned: No
E.8.4 The trial involves multiple sites in the Member State concerned: Yes
E.8.5 The trial involves multiple Member States: Yes
E.8.6 Trial involving sites outside the EEA
E.8.6.1 Trial being conducted both within and outside the EEA: Yes
E.8.6.2 Trial being conducted completely outside of the EEA: Information not present in EudraCT
E.8.6.3 If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned:
E.8.7 Trial has a data monitoring committee: Information not present in EudraCT
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial: 
E.8.9 Initial estimate of the duration of the trial
E.8.9.1 In the Member State concerned years: 1
E.8.9.1 In the Member State concerned months: 3
E.8.9.1 In the Member State concerned days: 
E.8.9.2 In all countries concerned by the trial years: 1
E.8.9.2 In all countries concerned by the trial months: 3

F. Population of Trial Subjects
F.1 Age Range
F.1.1 Trial has subjects under 18: No
F.1.1.1 In Utero: Information not present in EudraCT
F.1.1.2 Preterm newborn infants (up to gestational age < 37 weeks): Information not present in EudraCT
F.1.1.3 Newborns (0-27 days): Information not present in EudraCT
F.1.1.4 Infants and toddlers (28 days-23 months): Information not present in EudraCT
F.1.1.5 Children (2-11years): Information not present in EudraCT
F.1.1.6 Adolescents (12-17 years): Information not present in EudraCT
F.1.2 Adults (18-64 years): Yes
F.1.3 Elderly (>=65 years): Yes
F.2 Gender
F.2.1 Female: Yes
F.2.2 Male: Yes
F.3 Group of trial subjects
F.3.1 Healthy volunteers: No
F.3.2 Patients: Yes
F.3.3 Specific vulnerable populations: Information not present in EudraCT
F.3.3.1 Women of childbearing potential not using contraception  
(For clinical trials recorded in the database before the 10th March 2011 this question read: "Women of childbearing potential" and
did not include the words "not using contraception". An answer of yes could have included women of child bearing potential whether
or not they would be using contraception. The answer should therefore be understood in that context. This trial was recorded in the
database on 2006-07-06) : Yes
F.3.3.2 Women of child-bearing potential using contraception: Information not present in EudraCT
F.3.3.3 Pregnant women: No
F.3.3.4 Nursing women: No
F.3.3.5 Emergency situation: No
F.3.3.6 Subjects incapable of giving consent personally: No
F.3.3.7 Others: No
F.4 Planned number of subjects to be included
F.4.1 In the member state: 100
F.4.2 For a multinational trial
F.4.2.1 In the EEA: 900
F.4.2.2 In the whole clinical trial: 2000

G. Investigator Networks to be involved in the Trial


N. Review by the Competent Authority or Ethics Committee in the country concerned
N. Competent Authority Decision: Authorised
N. Date of Competent Authority Decision: 2006-05-06
N. Ethics Committee Opinion of the trial application: Favourable
N. Ethics Committee Opinion: Reason(s) for unfavourable opinion:
N. Date of Ethics Committee Opinion: 2006-05-18

P. End of Trial
P. End of Trial Status: Completed

